The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 10, 2013

Filed:

Feb. 19, 2009
Applicants:

Ian Collins, London, GB;

John Charles Reader, Cambridge, GB;

David Hugh Williams, Cambridge, GB;

Sukhbinder Singh Klair, Cambridge, GB;

Jane Elizabeth Scanlon, Cambridge, GB;

Nelly Piton, Cambridge, GB;

Michael Cherry, Cambridge, GB;

Inventors:

Ian Collins, London, GB;

John Charles Reader, Cambridge, GB;

David Hugh Williams, Cambridge, GB;

Sukhbinder Singh Klair, Cambridge, GB;

Jane Elizabeth Scanlon, Cambridge, GB;

Nelly Piton, Cambridge, GB;

Michael Cherry, Cambridge, GB;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/497 (2006.01); A61K 31/5377 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 413/14 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicyclylaryl-aryl-amines compounds of the following formula (referred to herein as BCAA compounds), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation:


Find Patent Forward Citations

Loading…